A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

October 28, 2026 updated by: Prelude Therapeutics Incorporated

A Phase 1, Open-Label, Multi-Center, Safety and Efficacy Study of PRT12396 in Participants With Polycythemia Vera and Myelofibrosis

This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This first-in-human, open-label, multi-center Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF). Eligible MF populations include participants with intermediate-1, intermediate-2, or high-risk primary MF, as well as post-polycythemia vera MF or post-essential thrombocythemia MF, with evidence of disease burden based on splenomegaly.

The study is conducted in two parts:

Part 1 (dose escalation) evaluates escalating oral doses of PRT12396 to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]).

Part 2 (dose expansion) enrolls additional participants at selected dose level(s) to further characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in the PV and MF populations.

Approximately up to 100 participants are planned for enrollment across both parts of the study.

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Recruiting
        • Royal Adelaide Hospital
    • Victoria
      • Clayton, Victoria, Australia, 3168
        • Recruiting
        • Monash Health, Monash Medical Centre
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Recruiting
        • One Clinical Research
      • Nice, France, 06200
        • Recruiting
        • Nice University Medicâl Center (CHU Nice, Hôpital Archet 1)
      • Paris, France, 75010
        • Recruiting
        • Saint-Louis Hospital
      • Toulouse, France, 31059
        • Recruiting
        • Oncopole Claudius Regaud
      • Florence, Italy, 50134
        • Recruiting
        • Azienda Ospedaliero Universitaria Careggi
      • Barcelona, Spain, 08036
        • Recruiting
        • Hospital Clinic de Barcelona
      • Madrid, Spain, 28034
        • Recruiting
        • Hospital Universitario Ramon y Cajal
      • Madrid, Spain, 28041
        • Recruiting
        • Hospital Universitario 12 de Octubre
      • Valencia, Spain, 46010
        • Recruiting
        • Hospital Clínico Universitario de Valencia
    • California
      • Los Angeles, California, United States, 90095
        • Recruiting
        • UCLA Ronald Reagan Medical Center
      • Sacramento, California, United States, 95817
        • Recruiting
        • University of California, Davis Comprehensive Cancer Center
    • Colorado
      • Denver, Colorado, United States, 80218
        • Recruiting
        • Colorado Blood Cancer Institute
    • Florida
      • Coral Springs, Florida, United States, 33065
        • Recruiting
        • BRCR Global - Coral Springs
      • Miami, Florida, United States, 33136
        • Recruiting
        • Sylvester Comprehensive Cancer Center
      • Tampa, Florida, United States, 33612
        • Recruiting
        • Moffitt Cancer Center
    • Michigan
      • Grand Rapids, Michigan, United States, 49546
        • Recruiting
        • START Midwest, LLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • Recruiting
        • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office
    • Tennessee
      • Nashville, Tennessee, United States, 37203
        • Recruiting
        • Tristar BMT
      • Nashville, Tennessee, United States, 37203
        • Recruiting
        • Tennessee Oncology, PLLC - Investigational Drug Services
    • Texas
      • Houston, Texas, United States, 77030
        • Recruiting
        • The University of Texas, MD Anderson Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures.
  • Confirmed diagnosis of PV or MF according to WHO 2016 or revised ICC/WHO 2022 criteria
  • Documented presence of a JAK2 V617 mutation
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Estimate life expectancy of ≥12 weeks per investigator assessment.
  • Negative serum or urine pregnancy test and agree to use contraception or maintain true abstinence.
  • Adequate organ function and bone marrow reserves (hematology, renal, and hepatic)

Exclusion Criteria:

  • History of another malignancy within 3 years prior to enrollment, except for malignancy considered cured with low risk of recurrence.
  • Clinically significant anemia due to nutritional deficiency or hemolytic disorders.
  • Active or uncontrolled infection requiring systemic therapy or hospitalization.
  • Any other medical or psychiatric conditions that, in the Investigator's judgment, would increase risk or interfere with study participation or interpretation of results.
  • Clinically significant or uncontrolled medical conditions, including active infection or cardiovascular disease, that would increase risk or interfere with study participation.
  • Unresolved toxicity Grade >1 from prior anticancer therapy, except for alopecia or peripheral neuropathy Grade ≤2.
  • Pregnancy or breastfeeding
  • Known sensitivity or contraindication to any component of study, or the excipients of study treatment.
  • Prior systemic therapy for PV or MF, prior or planned allogeneic hematopoietic stem-cell transplantation, recent major surgery, prior splenectomy or prior splenic irradiation, or use of hematopoietic growth factors within protocol-defined washout periods.
  • Use of strong or moderate cytochrome P450 (CYP) 3A4 inhibitor or inducer, sensitive CYP3A substrates with narrow therapeutic range, or acid-reducing agents that cannot be discontinued prior to study treatment.
  • Participation in another interventional clinical study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PRT12396: MF

Participants with myelofibrosis receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE)

PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals.

Experimental: PRT12396: PV

Participants with polycythemia vera receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE)

PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dose limiting toxicity (DLT) of PRT12396
Time Frame: Through cycle 1 (4 weeks)

Incidence of dose limiting toxicities, defined according to protocol-specified criteria

Through cycle 1 (4 weeks)
Incidence and severity of Adverse events
Time Frame: Through study completion, an average of 2 years

Incidence and severity of treatment-emergent adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 6.0

Through study completion, an average of 2 years
Adverse Events Leading to Dose Modifications or Discontinuation
Time Frame: Through study completion, an average of 2 years

Incidence of AEs leading to dose reductions, dose interruptions, treatment discontinuations, and clinically significant laboratory abnormalities

Through study completion, an average of 2 years
Maximum tolerated dose (MTD) and Recommended Dose(s) for Expansion (RDE[s]) of PRT12396
Time Frame: Through study completion, an average of 2 years

Determination of the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]) based on evaluation of DLTs, safety, and tolerability data

Through study completion, an average of 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hematologic Response Rate (PV)
Time Frame: Through study completion, an average of 2 years

Proportion of participants with polycythemia vera (PV) achieving best overall hematologic response (complete hematologic response or partial hematologic response) from the overall response assessments by Investigator

Through study completion, an average of 2 years
Duration of Hematologic Response (PV)
Time Frame: Through study completion, an average of 2 years

Duration of hematologic response in PV participants, defined as the time from first documented response (best overall hematologic response) to disease progression or death, whichever comes first

Through study completion, an average of 2 years
Hematocrit Control Without Phlebotomy Requirements (PV)
Time Frame: Through study completion, an average of 2 years

Proportion of PV participants achieving and maintaining hematocrit control without phlebotomy, time to first phlebotomy, and frequency of phlebotomy

Through study completion, an average of 2 years
Spleen Response (MF)
Time Frame: Through study completion, an average of 2 years

Assessment of spleen response including proportion achieving protocol-specified reduction in spleen volume, time to spleen response, duration of spleen response, and reduction in palpable spleen length

Through study completion, an average of 2 years
Change from Baseline in Hemoglobin (MF)
Time Frame: Through study completion, an average of 2 years

Change from baseline in hemoglobin levels in MF participants

Through study completion, an average of 2 years
Change from Baseline in Platelet Count (MF)
Time Frame: Through study completion, an average of 2 years

Change from baseline in platelet count in MF participants

Through study completion, an average of 2 years
Change from Baseline in Absolute Neutrophil Count (MF)
Time Frame: Through study completion, an average of 2 years

Change from baseline in absolute neutrophil count in MF participants

Through study completion, an average of 2 years
Transfusion Independence (MF)
Time Frame: Through study completion, an average of 2 years

Proportion achieving transfusion independence and duration of transfusion independence as defined by protocol criteria

Through study completion, an average of 2 years
Maximum Observed Plasma Concentration (Cmax)
Time Frame: Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Maximum observed plasma concentration will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Time To Maximum Concentration (Tmax)
Time Frame: Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Time to maximum concentration will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Area under the plasma concentration versus time curve (AUC)
Time Frame: Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Area under the plasma concentration-time curve will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Terminal Elimination Half-life (T1/2)
Time Frame: Cycle 1 Day 1

Terminal elimination half-life will be calculated using non-compartmental analysis

Cycle 1 Day 1
Steady State Trough Concentrations
Time Frame: Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Steady state trough concentrations will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Clearance
Time Frame: Cycle 1 Day 1

Clearance will be calculated using non-compartmental analysis

Cycle 1 Day 1
Accumulation
Time Frame: Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Accumulation will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)
Time Frame: Through study completion, an average of 2 years

Patient-reported outcomes assessed using the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS), evaluated as change from baseline at protocol-specified time points. The MPN SAF TSS is a validated questionnaire in which individual symptoms are scored using a numeric rating scale ranging from 0 to 10, with 0 indicating no symptoms and 10 indicating the worst imaginable symptoms; higher scores indicate greater symptom severity.

Through study completion, an average of 2 years
Patient Global Impression of Change (PGI-C)
Time Frame: Through study completion, an average of 2 years

Participant reported outcomes assessed using the Patient Global Impression of Change (PGI-C), evaluated at protocol-specified time points. The PGI C is a global assessment scale in which participants rate their overall change in condition since baseline using a 7 point ordinal scale ranging from "very much improved" to "very much worse," with lower scores indicating improvement and higher scores indicating worsening of symptoms.

Through study completion, an average of 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 29, 2026

Primary Completion (Estimated)

April 1, 2028

Study Completion (Estimated)

April 1, 2028

Study Registration Dates

First Submitted

February 26, 2026

First Submitted That Met QC Criteria

March 9, 2026

First Posted (Actual)

March 13, 2026

Study Record Updates

Last Update Posted (Actual)

October 29, 2026

Last Update Submitted That Met QC Criteria

October 28, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • PRT12396-01
  • 2026-525484-40-00 (Ctis)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.